Onabotulinumtoxin-A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phase of the PREEMPT clinical program

被引：0

作者：

Dodick, D. W. ^{[1
]}

Aurora, S. K. ^{[2
]}

DeGryse, R. E. ^{[3
]}

Turkel, C. C. ^{[3
]}

Silberstein, S. D. ^{[4
]}

Lipton, R. B. ^{[5
]}

Diener, H-C ^{[6
]}

Brin, M. F. ^{[3
]}

机构：

[1] Mayo Clin Arizona, Phoenix, AZ USA

[2] Swedish Pain Ctr, Seattle, WA USA

[3] Allergan Pharmaceut Inc, Irvine, CA 92715 USA

[4] Jefferson Headache Ctr, Philadelphia, PA USA

[5] Albert Einstein Coll Med, Bronx, NY 10467 USA

[6] Univ Hosp Essen Hufelandstr, Dept Neurol, Essen, Germany

来源：

JOURNAL OF HEADACHE AND PAIN | 2010年 / 11卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S14 / S14

页数：1

共 50 条

[1] Onabotulinumtoxin-A treatment reduces pain intensity in adults with chronic migraine: pooled results from the double-blind, placebo-controlled phase of PREEMPT
Silberstein, S. D.
Aurora, S. K.
DeGryse, R. E.
Turkel, C. C.
[J]. JOURNAL OF HEADACHE AND PAIN, 2010, 11 : S12 - S12
[2] OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phase of the PREEMPT clinical program
Dodick, D. W.
Aurora, S. K.
Turkel, C. C.
DeGryse, R. E.
Silberstein, S. D.
Lipton, R. B.
Diener, H. C.
Brin, M. F.
[J]. TOXICON, 2013, 68 : 110 - 110
[3] OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results from the Double-Blind, Randomized, Placebo-Controlled Phase of the PREEMPT Clinical Program
Dodick, David W.
Aurora, Sheena K.
Turkel, Catherine C.
DeGryse, Ronald E.
Silberstein, Stephen D.
Lipton, Richard B.
Diener, Hans-Christopher
Brin, Mitchell F.
[J]. NEUROLOGY, 2010, 74 (09) : A281 - A281
[4] Onabotulinumtoxin a for treatment of chronic migraine: 75% responder analysis results from the double-blind, randomized, placebo-controlled phase of the preempt clinical program
Dodick, D. W.
Diener, H. -C.
Turkel, C. C.
DeGryse, R. E.
Brin, M. F.
[J]. CEPHALALGIA, 2011, 31 (01) : 87 - 87
[5] OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program
Dodick, David W.
Turkel, Catherine C.
DeGryse, Ronald E.
Aurora, Sheena K.
Silberstein, Stephen D.
Lipton, Richard B.
Diener, Hans-Christoph
Brin, Mitchell F.
[J]. HEADACHE, 2010, 50 (06): : 921 - 936
[6] OnabotulinumtoxinA Treatment Reduces Headache Duration in Adults with Chronic Migraine: Pooled Results from the Double-Blind, Randomized, Placebo-Controlled Phase of the PREEMPT Clinical Program
Dodick, D. W.
Diener, H. -C.
DeGryse, R. E.
Turkel, C. C.
[J]. HEADACHE, 2010, 50 : S58 - S59
[7] OnabotulinumtoxinA Treatment Reduces Pain Intensity and Suffering in Adults with Chronic Migraine: Pooled Results from the Double-Blind, Randomized, Placebo-Controlled Phase of the PREEMPT Clinical Program
Silberstein, S. D.
Aurora, S. K.
DeGryse, R. E.
Turkel, C. C.
[J]. HEADACHE, 2010, 50 : S8 - S8
[8] OnabotulinumtoxinA for Treatment of Chronic Migraine: 75% Responder Analysis Results from the Double-Blind, Randomized, Placebo-Controlled Phase of the PREEMPT Clinical Program
Dodick, David
Diener, H.
Turkel, Catherine
DeGryse, Ronald
Brin, Mitchell
[J]. NEUROLOGY, 2012, 78
[9] OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
Diener, H. C.
Dodick, D. W.
Aurora, S. K.
Turkel, C. C.
DeGryse, R. E.
Lipton, R. B.
Silberstein, S. D.
Brin, M. F.
[J]. CEPHALALGIA, 2010, 30 (07) : 804 - 814
[10] OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
Dodick, D.
Diener, H. C.
Turkel, C.
DeGryse, R.
Brin, M.
[J]. JOURNAL OF HEADACHE AND PAIN, 2013, 14

← 1 2 3 4 5 →